THROMBOPROPHYLAXIS IN THE EMERGENCY DEPARTMENT. ADEQUACY OF THE PRESCRIPTION.
5PSQ-127
PHARMACOLOGICAL RISK FACTORS FOR DRUG-DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV: A SYSTEMATIC REVIEW
5PSQ-126
EFFICACY AND SAFETY OF OMALIZUMAB, MEPOLIZUMAB AND BENRALIZUMAB IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA
5PSQ-125
BRIDGING ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION AFTER A TRANSURETHRAL RESECTION: PATIENT MANAGEMENT IS DONE APPROPRIATELY?
5PSQ-124
EFFECTIVENESS AND SAFETY OF ANTIRETROVIRAL TREATMENT SIMPLIFICATION TO DOLUTEGRAVIR+LAMIVUDINE OR DOLUTEGRAVIR+RILPIVIRINE IN OLDER ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS
5PSQ-123
IMPACT OF PHARMACOTHERAPEUTIC COMPLEXITY ON ADHERENCE TO ANTIRETROVIRAL TREATMENT IN OLDER ADULTS WITH HIV
5PSQ-122
COVID-19 VACCINE VIGILANCE: COMPARATIVE STUDY BETWEEN HOSPITAL, REGIONAL AND NATIONAL DATA
5PSQ-121
CYTOKINE RELEASE SYNDROME RELATED TO THE TREATMENT WITH TECLISTAMAB: A CASE REPORT
5PSQ-120
ANALYSIS OF THE PHARMACEUTICAL INTERVENTIONS PERFORMED ON ONCOHEMATOLOGICAL PATIENTS THROUGH AN ONCOHEMATOLOGY PHARMACY CONSULTATION
5PSQ-119
A NEW PHARMACEUTICAL CARE PROGRAMME FOR COVID-19 PATIENTS TREATED WITH PAXLOVID® : IMPLEMENTATION AND SAFETY OUTCOMES REPORTED
5PSQ-118
PATIENTS´ EXPERIENCE WITH SUBCUTANEOUS INJECTION SELF-ADMINISTRATION AND THE ROLE OF VIRTUAL REALITY
5PSQ-117
EVALUATION OF CARDIOTOXICITY BY OSIMERTINIB IN CLINICAL PRACTICE
5PSQ-116
PERSISTENCE OF INHIBITORS OF INTERLEUKIN-23 (anti-IL-23) FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (msPs) IN THE ROUTINE CLINICAL PRACTICE CONDITIONS.
5PSQ-115
DEPRESCRIBING LONG-TERM TREATMENTS WITH BIPHOSPHONATES. PHARMACEUTICAL INTERVENTION BRINGS VALUE.
5PSQ-114
PERSISTENCE AND LEVEL OF CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH GUSELKUMAB
